Gene expression profiling using Nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 4941-4950

  Beard, Rachel E ^a   Abate Daga, Daniel ^a   Rosati, Shannon F ^a   Zheng, Zhili ^a   Wunderlich, John R ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CSAG2 GENE; CSPG4 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IL13RA2 GENE; MAGEA3 GENE; MAGEC2 GENE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; NUCLEOTIDE SEQUENCE; PRAME GENE; PRIORITY JOURNAL; SOX10 GENE; UNINDEXED SEQUENCE;

ADULT; AGED; ANTIGENS, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NANOTECHNOLOGY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884539984     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1253     Document Type: Article

References (50)

1. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011;45:341-60.
2. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011;29:550-7.
3. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
4. Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 2012;25:854-8.
5. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
6. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimericantigenreceptor-transduced T cells. Blood 2012;119:2709-20.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
8. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-25.
9. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 2010;70:3027-33.
10. Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 2009;58:383-94.
11. Goff SL, Johnson LA, Black MA, Xu H, Zheng Z, Cohen CJ, et al. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother 2010;59:1551-60.
12. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133-51.
13. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
14. Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, et al. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg 2012;147:744-9.
15. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
16. Segal NH, Blachere NE, Guevara-Patino JA, Gallardo HF, Shiu HY, Viale A, et al. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 2005;5:2.
17. Bredenbeck A, Hollstein VM, Trefzer U, Sterry W, Walden P, Losch FO. Coordinated expression of clustered cancer/testis genes encoded in a large inverted repeat DNA structure. Gene 2008;415:68-73.
18. Chen Z, Zhu B, Wu Y. Expression of TRAG-3 antigen in non-small-cell lung carcinomas. Lung Cancer 2002;38:101-2.
19. Ohta M, Tanaka F, Sadanaga N, Yamaguchi H, Inoue H, Mori M. Expression of the TRAG-3 gene in human esophageal cancer: the frequent synchronous expression of MAGE-3 gene. Oncol Rep 2006;15:1529-32.
20. Wu YZ, Zhao TT, Ni B, Zou LY, Liu HL, Zhu B. Expression of TRAG-3 in breast cancer. Int J Cancer 2003;107:167-8.
21. Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, et al. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 2012;118:1845-55.
22. Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, et al. Identification of HLAA 0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 2003;9:1850-7.
23. Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, et al. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012;12:16.
24. Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, et al. A TCR targeting the HLA-A 0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 2011;186:685-96.
25. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, et al. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 2008;8:7.
26. Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G, et al. Expression and prognostic relevance of MAGE-C1/CT7 and MAGEC2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 2010;89:175-81.
27. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 2009;124:352-7.
28. Figueiredo DL, Mamede RC, Spagnoli GC, Silva WA Jr, Zago M, Neder L, et al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 2011;33:702-7.
29. Wen W, Zhang L, Peng J, Chen J, Hao J, Li X, et al. Identification of promiscuous HLA-DR-restricted CD4 (+) T-cell epitopes on the cancertestis antigen HCA587. Cancer Sci 2011;102:1455-61.
30. Xing Q, Pang XW, Peng JR, Yin YH, Li Y, Yu X, et al. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun 2008;372:331-5.
31. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg 2008;143:841-6.
32. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol 2006;33:2015-9.
33. Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012;18:5949-60.
34. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
35. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
36. Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res 2011;17:5615-25.
37. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, et al. High-avidity cytotoxic T lymphocytes specific for a new PRAMEderived peptide can target leukemic and leukemic-precursor cells. Blood 2011;117:3353-62.
38. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673-83.
39. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, et al. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012;18:5352-63.
40. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, et al. CSPG4 in cancer: multiple roles. Curr Mol Med 2010;10:419-29.
41. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010;102:1496-512.
42. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, et al. NG2 expression predicts the metastasis formation in softtissue sarcoma patients. J Orthop Res 2009;27:135-40.
43. Svendsen A, Verhoeff JJ, Immervoll H, Brogger JC, Kmiecik J, Poli A, et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 2011;122:495-510.
44. Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, et al. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 2011;71:7410-22.
45. Agnarsdottir M, Sooman L, Bolander A, Stromberg S, Rexhepaj E, Bergqvist M, et al. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res 2010;20:468-78.
46. Shin J, Vincent JG, Cuda JD, Xu H, Kang S, Kim J, et al. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. J Am Acad Dermatol 2012;67:717-26.
47. Zhong WD, Qin GQ, Dai QS, Han ZD, Chen SM, Ling XH, et al. SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer 2012;12:248.
48. Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol 2012;44:959-65.
49. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012;14:882-90.
50. Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res 2002;62:3020-3.